Related references
Note: Only part of the references are listed.Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
Christopher C. Kloss et al.
NATURE BIOTECHNOLOGY (2013)
Targeting of a Conformationally Exposed, Tumor-Specific Epitope of EGFR as a Strategy for Cancer Therapy
Hui K. Gan et al.
CANCER RESEARCH (2012)
Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas
Catherine A. Del Vecchio et al.
EXPERT REVIEW OF VACCINES (2012)
Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma
Richard A. Morgan et al.
HUMAN GENE THERAPY (2012)
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer
David F. Stroncek et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
Chrystal U. Louis et al.
BLOOD (2011)
Two signal models in innate immunity
Mary F. Fontana et al.
IMMUNOLOGICAL REVIEWS (2011)
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients
Barbara Savoldo et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Michael Kalos et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Development of an EGFRvIII specific recombinant antibody
Puja Gupta et al.
BMC BIOTECHNOLOGY (2010)
Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen
Masasuke Ohno et al.
CANCER SCIENCE (2010)
Anti-GD3 Chimeric sFv-CD28/T-Cell Receptor ζ Designer T Cells for Treatment of Metastatic Melanoma and Other Neuroectodermal Tumors
Agnes S. Y. Lo et al.
CLINICAL CANCER RESEARCH (2010)
4-1BB and CD28 Signaling Plays a Synergistic Role in Redirecting Umbilical Cord Blood T Cells Against B-Cell Malignancies
Syam Tammana et al.
HUMAN GENE THERAPY (2010)
Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell-mediated Tumor Eradication
Xiao-Song Zhong et al.
MOLECULAR THERAPY (2010)
Genetically engineered T cells to target EGFRvIII expressing glioblastoma
Szofia S. Bullain et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme
John H. Sampson et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
Carmine Carpenito et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Antitumor activity of chimeric immunoreceptor gene-modified Tc1 and Th1 cells against autologous carcinoembryonic antigen-expressing colon cancer cells
Takeshi Sasaki et al.
CANCER SCIENCE (2006)
Functional evaluation of DC-SIGN monoclonal antibodies reveals DC-SIGN interactions with ICAM-3 do not promote human immunodeficiency virus type 1 transmission
L Wu et al.
JOURNAL OF VIROLOGY (2002)
Share Paper
